News articles about Celyad (NASDAQ:CYAD) have trended somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Celyad earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.1404058524609 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of Celyad (NASDAQ:CYAD) opened at $40.39 on Monday. Celyad has a 52-week low of $16.73 and a 52-week high of $64.75.

A number of analysts recently weighed in on CYAD shares. Piper Jaffray Companies reiterated a “buy” rating and issued a $49.00 price target (up from $35.00) on shares of Celyad in a research report on Friday, September 1st. ValuEngine downgraded shares of Celyad from a “hold” rating to a “sell” rating in a research report on Friday.

WARNING: This article was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at

Celyad Company Profile

Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle.

Insider Buying and Selling by Quarter for Celyad (NASDAQ:CYAD)

Receive News & Ratings for Celyad SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad SA and related companies with's FREE daily email newsletter.